Annual report pursuant to Section 13 and 15(d)

Consolidated Balance Sheets (Parenthetical)

v3.19.2
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Jun. 30, 2019
Jun. 30, 2018
Accounts payable, related parties $ 65 $ 189
Accrued expenses, related parties $ 699 $ 789
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 275,000,000 275,000,000
Common stock, shares issued (in shares) 20,152,458 16,040,126
Common stock, shares outstanding (in shares) 20,152,458 16,040,126
Series A Preferred Stock [Member]    
Preferred stock, par value (in dollars per share) $ 1,000 $ 1,000
Preferred stock, shares authorized (in shares) 6,300 6,300
Preferred stock, shares issued (in shares) 3,987 6,210
Preferred stock, shares outstanding (in shares) 3,987 6,210
Series B Preferred Stock [Member]    
Preferred stock, par value (in dollars per share) $ 1,000 $ 1,000
Preferred stock, shares authorized (in shares) 5,785 5,785
Preferred stock, shares issued (in shares) 5,785 5,785
Preferred stock, shares outstanding (in shares) 5,785 5,785
iBio CMO [Member]    
Preferred stock, par value (in dollars per share) $ 0 $ 0
Preferred stock, shares authorized (in shares) 1,000,000 1,000,000
Preferred stock, shares issued (in shares) 1 1
Preferred stock, shares outstanding (in shares) 1 1